Common questions about Udenyca (FAQ)
Q: What is the difference between Udenyca and Neulasta?
Udenyca (pegfilgrastim-cbqv) is designated by regulatory agencies as a biosimilar to the reference product, Neulasta (pegfilgrastim). This classification means Udenyca is highly similar to Neulasta and is considered to have no clinically meaningful differences in terms of safety, purity, and potency. Both medicines are indicated for the same medical uses.
Q: What does 'biosimilar' mean in relation to Udenyca?
A biosimilar is a type of biological medicine that is officially approved because it has been shown to be highly similar to an already-approved reference product. According to regulatory guidance, a biosimilar is not considered to have any meaningful clinical difference from the reference product and is indicated for the same medical conditions as the reference product.
Q: What is the significance of the suffix '-cbqv' in the drug name pegfilgrastim-cbqv?
The four-letter suffix -cbqv is a distinguishing marker that is required by the FDA for all non-interchangeable biosimilar products. Its purpose is solely to clearly identify the product and distinguish it from its reference drug and other biosimilars in the same drug class, but it does not have any specific medical meaning or function.
Q: How is the On-body Injector (OBI) version of Udenyca different from the prefilled syringe?
The On-body Injector (OBI) for Udenyca is an automated delivery device that is applied to the skin by a healthcare professional. It is programmed to automatically deliver the medication approximately 27 hours after placement over a short, five-minute period. In contrast, the prefilled syringe requires a manual subcutaneous injection.
Q: Is it normal to feel bone pain after receiving Udenyca?
According to official regulatory documents, bone pain is classified as a very common adverse reaction, meaning it has been reported in 10% or more of patients during clinical studies. It is the most frequently observed reaction associated with this medication.
Q: How long do the common side effects of Udenyca usually last?
Regulatory documents do not provide a specific duration for how long common side effects last. However, common side effects are anticipated to be temporary, which is consistent with the drug’s period of activity in the body after a single dose.
Q: Can Udenyca cause long-term side effects?
Regulatory documents note that the risk of developing Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) may be increased in certain cancer patients receiving chemotherapy and/or radiotherapy. These conditions can sometimes manifest in the long term, and this risk is noted in the official warnings.
Q: How quickly after injection does Udenyca start to raise white blood cell counts?
Studies related to the drug's activity show that white blood cell counts begin to increase within 24 to 72 hours after administration. The drug’s peak effect often occurs a few days later.
Q: Is it safe to drink alcohol while using Udenyca?
Official regulatory documents do not list any specific interactions with alcohol. The documented constraints for Udenyca relate only to the timing of its co-administration with cytotoxic chemotherapy.
Q: What is the youngest age a patient can be to receive Udenyca?
Udenyca is approved for use in pediatric patients. The official dosage guidelines provide specific weight-based dosing for the youngest patients, including a dose for those weighing less than 10 kg.
Q: Can patients who have kidney problems use Udenyca?
Regulatory documents state that no specific dose adjustment is typically required for patients with renal impairment (kidney problems). However, one of the serious adverse reactions noted is Glomerulonephritis, a condition involving the kidneys.
Q: Is Udenyca safe to use during pregnancy?
Official regulatory documents state that there are no adequate and well-controlled studies of Udenyca use in pregnant women to fully determine any drug-associated risk of adverse developmental outcomes. The potential risks of use during pregnancy are part of the considerations described in the official label.
Q: Can a patient breastfeed while receiving Udenyca?
There are no official data regarding the presence of Udenyca products in human milk, or what the effects might be on a breastfed child or on milk production. The official label notes that this class of drugs is not typically absorbed orally by infants.
Q: What are the clinical benefits that studies have shown for Udenyca?
Studies for the drug class have demonstrated that its use leads to a reduction in the incidence of infection associated with low white blood cell counts, which is known as febrile neutropenia. This benefit has been observed in patients undergoing myelosuppressive chemotherapy.
Q: What is the longest time a patient can wait after chemo to receive Udenyca?
Official guidelines state that Udenyca must not be administered between 14 days before and 24 hours after receiving cytotoxic chemotherapy. The administration rule requires a minimum separation of 24 hours following chemotherapy.
Q: What happens if the On-body Injector falls off before the dose is finished?
If the On-body Injector falls off the skin at any point, official patient instructions advise not to attempt to reapply the device. Patients are instructed to immediately contact a healthcare provider for guidance, as a replacement dose may be required.
Q: What does a flashing red light on the On-body Injector mean?
A flashing red light on the On-body Injector is the device's signal that an injector error has occurred. Patient instructions require that if this indicator appears, you should immediately contact your healthcare provider for assistance and direction.
Q: Should I avoid certain activities or places while wearing the On-body Injector?
Instructions advise avoiding activities such as traveling, driving, or operating heavy machinery during the automated delivery window (which occurs about 27 hours after application). You should also avoid sleeping on the device and using bathtubs or saunas while wearing it.
Q: What should be avoided near the On-body Injector (e.g., cell phones, heat)?
Official regulatory documents state that you should avoid exposing the device to environments like diagnostic imaging (CT, MRI, X-ray), radiation treatment, or oxygen-rich environments. Patients are also advised to keep it at least 10 cm (4 inches) away from certain electronic devices, such as cell phones, during the delivery cycle.
Q: Can Udenyca be used to treat an existing infection?
Udenyca is officially indicated to reduce the incidence of infection associated with low white blood cell counts, which is a preventive use. The medicine is not indicated as a treatment for an active or established infection.
Q: How does Udenyca help people exposed to high doses of radiation?
Udenyca is indicated in official documents to increase survival in patients who have been acutely exposed to myelosuppressive doses of radiation. This is a condition officially known as Hematopoietic Subsyndrome of Acute Radiation Syndrome.
Q: Are there any known allergic reaction symptoms associated with Udenyca?
Serious allergic reactions, including anaphylaxis, are listed as possible in the safety documents. Symptoms may include rash, itching, swelling of the face, mouth, or throat, difficulty breathing, or dizziness.
Q: Why do some people report severe pain from Udenyca but others do not?
The specific reason for varying pain sensitivity is not fully described in regulatory materials. However, the bone pain that occurs is believed to be related to the drug's mechanism of stimulating the rapid proliferation and release of white blood cells from the bone marrow, which creates pressure inside the bone cavity.
Q: Does Udenyca make a patient more tired or fatigued?
Fatigue or tiredness is not listed among the most common adverse reactions in the official label, such as bone pain or headache. However, fatigue is noted in post-marketing reports or literature as having been reported.
Q: Is it necessary to have blood tests done while receiving Udenyca?
Official guidelines recommend obtaining a baseline complete blood count (CBC) before administration when the drug is used for radiation exposure. Monitoring of white blood cell counts is often implemented during treatment with this class of medication.
Q: What is the purpose of taking an antihistamine before or after a Udenyca shot?
The official product label does not provide any guidance, recommendations, or instruction for the prophylactic or concurrent use of antihistamines. Use of additional medications is a matter for discussion with the prescribing healthcare provider.
Q: Can Udenyca cause joint pain in the hands or feet?
Regulatory documents list pain in extremities (limbs) as a common adverse reaction, which is classified under Musculoskeletal disorders. This category includes potential pain occurring in areas like the hands or feet.
Q: What is Capillary Leak Syndrome and is it a risk with Udenyca?
Capillary Leak Syndrome (CLS) is listed in the official warnings as a rare, serious adverse reaction. This condition involves leakage of fluid and protein from the blood vessels into surrounding tissues, which can result in a life-threatening drop in blood pressure.
